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N on-invasive prenatal genetic testing (NIPT) is indeterminate when the fetus-derived cell-free 
DNA concentration in the blood is low [1-4],  and the 
mechanism thereof has not been completely elucidated.  
We experienced a case in which a re-examination of an 
“indefinite” fetus gave a positive trisomy 18 reading,  the 
amniotic fluid chromosomal test subsequently carried 
out for a definite diagnosis revealed a normal karyotype,  
and confined placental mosaicism (CPM) was observed 
in a microarray analysis of the placenta.  We hereby 
report on the issues with NIPT as well as suggestions for 
resolving them.
Case Report
The mother was a 39-year-old women,  primigrav-
ida.  There was nothing worthy of special mention 
regarding her family history and past history.  Her hus-
band was 46 years old.  She became pregnant by intra-
cytoplasmic sperm injection.  Based on her older 
maternal age,  she was referred as an outpatient to the 
Genetic Counseling Department in our hospital,  where 
she underwent NIPT at 15 weeks and 2 days of preg-
nancy.  At 17 weeks and 5 days of pregnancy,  she 
underwent NIPT again following post-examination 
counseling.  The false positive trisomy 18 test results 
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We experienced a case of advanced maternal age in which a fetus was found to be positive for trisomy 18 at 
re-examination following indeterminate non-invasive prenatal genetic testing (NIPT),  the amniotic fluid chro-
mosomal test revealed a normal karyotype,  and confined placental mosaicism (CPM) was observed in an SNP 
microarray analysis of the placenta.  The child was born with no defects or complications.  In the present case,  
the result of the original NIPT at week 15 of pregnancy was indeterminate and the subsequent re-examination 
result was positive; since the definitive normal diagnosis was not reported until the latter half of week 21,  the 
pregnant patient was subjected to psychological stress for a long period of time.  The problem with NIPT is that 
most of the fetus-derived cell-free DNA in the maternal blood is not derived directly from the fetus but from the 
villus cells of the placenta,  leading to indefinite diagnoses; for that reason,  the pregnant patient was subjected 
to psychological stress for a long period of time.  Of the 18,251 cases undergoing NIPT in the past 2 years in 
Japan,  51 had indeterminate results; this was the second case in which a subsequent re-examination gave a pos-
itive result for trisomy 18.
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were revealed at 19 weeks and 4 days of pregnancy,  and 
chromosomal testing of her amniotic fluid was carried 
out the following day.  A fetal ultrasound was also car-
ried out at this time; however,  no clear findings sug-
gesting chromosomal abnormalities in the fetus were 
found.  Upon probing the company that conducted the 
test as to why it took so long for the results to appear,  
they responded that the first test had been positive for 
trisomy 18,  but was not informative because the target 
chromosomal concentration level was near the standard 
cut-off level.  Upon re-testing by NIPT,  one specimen 
was negative,  but trisomy 18 positive was observed in 
other specimens and so it was ultimately determined as 
“positive.” Fluorescence in situ hybridization (FISH) was 
returned at 20 weeks and 5 days of pregnancy,  confirm-
ing that the 18th chromosome was normal.  The final 
report may have extended beyond 22 weeks of preg-
nancy,  and so the patient agreed to make a decision 
regarding continuing pregnancy after the interim 
report.  At 21 weeks and 5 days of pregnancy,  chromo-
somal testing of the patient’s amniotic fluid revealed 
that the karyotype was 46 , XX (Fig. 1),  and the couple 
was told that CPM might be the cause thereof.  CPM 
causes placental insufficiency,  leading to fetal growth 
restriction; therefore,  perinatal period management 
was subsequently carried out at our hospital.  
Fortunately,  fetal development and the course of preg-
nancy were both good.  She went into labor at 39 weeks 
and 5 days of pregnancy,  and delivered a 3,306 g baby 
girl whose Apgar scores were 8 and then 9 at 1 and then 
5 min,  respectively.  The child was not observed with 
any external malformations,  and the extracted placenta 
was subjected to pathologic and chromosomal testing.  
In the placenta pathology,  marginal attachment of the 
umbilical cord,  venous dilatation and partial angiitis of 
the placenta surface were observed (Fig. 2); however,  
villus growth corresponding to several weeks was 
observed with no clear observation of abnormal find-
ings.  At the same time,  regarding chromosomal testing 
of the placenta,  SNP microarray analysis was carried 
out and arr (18) × 2-3 was found (Fig. 3).  The estimated 
percent mosaicism of cells with trisomy 18 is 40-50%.  
Because the previous amniocentesis on this pregnancy 
showed normal female results (46 , XX),  the trisomy 18 
cells in this microarray analysis likely represent con-
fined placental mosaicism.
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Fig. 1　 Conventional karyotype analysis of cultured amniocytes shows the fetal karyotype as 46 ,XX.
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Fig. 3　 SNP microarray result showing the presence of mosaicism of placental tissue.  A,  Summary of SNP microarray analysis showing 
a high density of short runs of allele homozygosity throughout the genome; B,  A full view of chromosome 18; C,  Detailed results of SNP 
microarray analysis,  showing (from top to bottom) the smooth signal,  copy number state,  log2 ratio,  and B allele frequency,  identifying 
mosaicism for trisomy 18.
Discussion
In the present case,  the indefinite results of NIPT at 
week 15 of pregnancy and the false positive results of 
the subsequent re-examination resulted in the definite 
diagnosis being delayed until the latter half of week 21,  
such that the pregnant patient was subjected to psycho-
logical stress for a long period of time.  The present case 
provides 2 clinical suggestions.  Most fetus-derived cell-
free DNA in the blood plasma of the maternal body is 
derived from trophoblastic cells of the placenta and not 
the fetus; such a source cannot provide a definite diag-
nosis via NIPT.  Although CPM may be diagnosed (or 
inferred) prenatally by chorionic villus sampling (CVS) 
or NIPT [5 , 6],  these methods are not routinely per-
formed and most CPM that occurs in pregnancy is 
never diagnosed.  Since there are cases of normal devel-
opment such as the present case,  it is difficult to screen 
which cases should be suspected as suffering from 
CPM.
It is known that fetal cell-free DNA in maternal 
peripheral blood originates from trophoblasts and 
mainly consists of placental DNA [7 , 8].  That is,  NIPT 
is a test used to analyze placenta-derived DNA,  allow-
ing secondary results reflecting the pathology of the 
placenta to be observed [1 , 2].  While the majority of 
NIPT results in Japan are generally “positive” or “nega-
tive,” the result “not informative” is observed in 0.1% of 
cases [9].  The NIPT method adopted at our hospital is 
Massively Parallel Sequencing (MPS) using a next-gen-
eration sequencer; this method involves the detection 
of quantitative changes in each chromosome-derived 
component in cell-free DNA in the blood plasma of the 
maternal body to detect chromosome number abnor-
malities of the fetus [1-4].  Specifically,  the base 
sequence of each fragment of cell-free DNA in the 
blood plasma of the maternal body is determined by a 
sequencer,  with derived chromosomes determined via 
comparison with human genome information; how-
ever,  samples with low fetal DNA in the blood plasma 
of the maternal body and samples with a low Z-score 
(index number of concentration changes of the con-
cerned chromosome) are excluded,  making results 
indeterminate.  It is believed that these features may 
reflect CPM and related changes in the maternal body 
and fetus.  Moreover,  most CPM occurring during 
pregnancy is not diagnosed,  making classification of 
cases difficult.  Many reports have mentioned that the 
placenta plays a major role in the onset of fetal diseases 
including abnormal fetal development accompanying 
pregnancy,  and that CPM is present in approximately 
10% of placentas associated with fetal growth restriction 
pregnancies (after excluding constitutional chromo-
somal abnormalities) [10-13]; research has also sug-
gested that CPM is considerably more likely when pla-
cental insufficiency occurs in the presence of older 
maternal age [13].  However,  the actual incidence of 
onset has not been clarified.  If CPM is even suspected,  
careful perinatal management attending to the risk of 
fetal dysfunction and preeclampsia is required,  but the 
prognosis of the child changes depending on the 
involved chromosome and the mosaic type,  or the 
cause of onset.  This makes the provision of accurate 
information during genetic counseling before and after 
pregnancy very important.
It has been suggested that the cause of false positive 
or not informative NIPT results may be as varied as 
CPM,  submicroscopic chromosomal abnormalities,  a 
vanishing twin,  complications of tumors accompanying 
chromosomal aneuploidy of the maternal body,  etc. 
[14].  However,  the mechanism(s) thereof have not been 
completely elucidated.  Elucidating false positives and 
the pathology of postponed determination is important 
in terms of inferring pregnancy prognoses; further 
development in our analytic capabilities would allow 
worried pregnant women and their physicians to be 
provided with reliable information.  The experience of 
using NIPT in clinical practice confirms that abnormal 
results cannot be considered diagnostic.  Pre-test 
genetic counseling should emphasize this.  Diagnostic 
genetic testing such as amniocentesis should always be 
offered immediately after abnormal NIPT results are 
obtained.
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